Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
Researchers are seeking the best dose of cirtuvivint to use alone and with ASTX727 for leukemia and myelodysplastic syndromes (MDS). The people in this study have acute myeloid leukemia (AML) or MDS that keeps growing after treatment.
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
Researchers in this study are comparing two different treatments for hairy cell leukemia. The people in this study have hairy cell leukemia that has not yet been treated. In addition, their leukemia has a genetic mutation (change) called BRAF V600E.
Researchers want to find the best dose of 225Ac-ABD147 to treat advanced lung cancer. The people in this study have small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma of the lung (LCNEC). Their cancer keeps growing even after treatment that included platinum-based chemotherapy.
Researchers are comparing IMA203 cellular therapy with standard treatment in people with melanoma of the skin. Their melanoma is inoperable (cannot be surgically removed) or metastatic (has spread) and keeps growing despite treatment.
Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
